AbbVie (NYSE:ABBV) Stock Rating Reaffirmed as Buy by Guggenheim

AbbVie (NYSE:ABBV)‘s stock had its “buy” rating reaffirmed by investment analysts at Guggenheim in a research report issued on Friday, Benzinga reports. They presently have a $288.00 price target on the stock. Guggenheim’s price objective suggests a potential upside of 4.82% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on ABBV. Barclays boosted their price target on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Wells Fargo & Company upped their target price on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. BNP Paribas Exane upped their target price on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Morgan Stanley upped their target price on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Royal Bank Of Canada upped their target price on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $276.64.

AbbVie Price Performance

Shares of ABBV stock traded up $2.32 during trading hours on Friday, reaching $274.74. 403,174 shares of the company were exchanged, compared to its average volume of 6,397,756. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $276.61. The stock’s fifty day moving average is $258.56 and its two-hundred day moving average is $236.35. The company has a market cap of $485.41 billion, a price-to-earnings ratio of 77.88, a P/E/G ratio of 1.23 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts anticipate that AbbVie will post 14.01 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ABBV. Vilga Financial Planning LLC lifted its stake in AbbVie by 4.2% in the third quarter. Vilga Financial Planning LLC now owns 1,376 shares of the company’s stock valued at $360,000 after acquiring an additional 55 shares during the last quarter. Market Street Wealth Management Advisors LLC lifted its stake in AbbVie by 11.2% in the third quarter. Market Street Wealth Management Advisors LLC now owns 1,258 shares of the company’s stock valued at $329,000 after acquiring an additional 127 shares during the last quarter. Monument Capital Management lifted its stake in AbbVie by 6.7% in the third quarter. Monument Capital Management now owns 6,936 shares of the company’s stock valued at $1,814,000 after acquiring an additional 433 shares during the last quarter. Emergent Wealth Advisors LLC lifted its stake in AbbVie by 1.9% in the third quarter. Emergent Wealth Advisors LLC now owns 3,221 shares of the company’s stock valued at $842,000 after acquiring an additional 60 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. lifted its stake in AbbVie by 1.4% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 522,459 shares of the company’s stock valued at $136,670,000 after acquiring an additional 7,100 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts raised targets and reaffirmed bullish ratings. Guggenheim reaffirmed its “buy” rating with a $288 price target, while JPMorgan raised its target to $300 and maintained an “overweight” rating. Cantor Fitzgerald also lifted its target to $290 and kept an “overweight” rating. The revisions indicate continued confidence in AbbVie’s earnings outlook and growth prospects.
• Positive Sentiment: Temab-A received two FDA Breakthrough Therapy Designations. AbbVie’s telisotuzumab adizutecan (Temab-A, or ABBV-400) received the designations for potential use in colorectal cancer and non-small cell lung cancer. The FDA status may accelerate development and review, strengthening the perceived value of AbbVie’s oncology pipeline. FDA Grants Breakthrough Therapy Designations to AbbVie’s Temab-A
• Positive Sentiment: Additional oncology data supported pipeline optimism. An AbbVie and Genmab combination involving epcoritamab reportedly reduced the risk of progression or death by 51% in diffuse large B-cell lymphoma, providing another favorable signal for AbbVie’s cancer portfolio.
• Positive Sentiment: Momentum has pushed ABBV to new one-year highs. The stock recently set consecutive 52-week highs, suggesting that analyst upgrades and pipeline news are reinforcing positive investor sentiment.
• Neutral Sentiment: Valuation and expectations remain important risks. AbbVie is trading near its 12-month high with a relatively elevated price-to-earnings ratio, so further gains may depend on the company delivering against strong earnings and pipeline expectations. Recent coverage also noted mixed growth outlooks across large pharmaceutical companies, despite higher price targets.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.